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efit of anti-inflammatory medications such as the cyclo-oxy-
genase-2 inhibitors, TNF-α antagonists and others, and the 
anti-inflammatory and immunomodulatory intrinsic effects 
of antidepressants.  © 2014 S. Karger AG, Basel
 Introduction
 Activation of the inflammatory response system in ma-
jor depression (MD) is well documented  [1–5] . Two re-
cent meta-analyses clearly showed elevated interleukin 
(IL)-6 levels in patients with MD  [6, 7] . However, the find-
ings of the two meta-analyses differed regarding levels of 
the inflammatory markers C-reactive protein (CRP), IL-1, 
IL-1RA and tumor necrosis factor (TNF)-α. In general, 
the inflammatory response system appears to be activated, 
but the levels of the different markers vary across studies. 
MD is a disorder often triggered by stress. It has been 
shown that – often based on genetic disposition – early-
life stress or separation stress are associated with an in-
crease of proinflammatory cytokines leading to an activa-
tion of the immune system and proinflammatory prosta-
glandins. Prostaglandin E2 (PGE2) is an important 
mediator of inflammation  [8] . Increased PGE2 in the sa-
liva, serum and cerebrospinal fluid (CSF) of depressed pa-
tients has been described previously  [9–12] . The enzyme 
cyclooxygenase-2 (COX-2) is involved in the function of 
PGE2 in the inflammatory pathway. In the brain, the ac-
tivation of microglia cells and astrocytes is crucial, because 
proinflammatory molecules are produced and released in 
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 Abstract
 High levels of several proinflammatory components of the 
immune system, such as interleukin-6, C-reactive protein, tu-
mor necrosis factor (TNF)-α, or neopterin in patients suffer-
ing from major depression (MD) point to the involvement of 
an inflammatory process in the pathophysiology of MD. The 
direct and indirect effects of cytokines on neurotransmitter 
storage and release – mediated by microglia cells and astro-
cytes – are discussed. The tryptophan/kynurenine metabo-
lism is one of the indirect mechanisms because the enzyme 
indoleamine 2,3-dioxygenase – a key enzyme of this metab-
olism in the central nervous system – is driven by pro- and 
anti-inflammatory cytokines and degrades serotonin. More-
over, neuroactive kynurenines such as kynurenic acid and 
quinolinic acid act on the glutamatergic neurotransmission 
as N-methyl- D -aspartate antagonists and agonists, respec-
tively. Alterations of the serotonergic, noradrenergic and 
glutamatergic neurotransmission have been shown with 
low-level neuroinflammation and may be involved in symp-
tom generation. Epidemiological and clinical studies show a 
role for inflammation as a risk factor for MD. A large-scale 
epidemiological study in MD clearly demonstrates that se-
vere infections and autoimmune disorders are lifetime risk 
factors for MD. The vulnerability-stress-inflammation model 
matches with this view as stress may increase proinflamma-
tory cytokines and even contribute to a lasting proinflamma-
tory state. Further support comes from the therapeutic ben-
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the brain. The interactions between the immune system 
and neurotransmitters, the tryptophan/kynurenine sys-
tem, and the glutamatergic neurotransmission are further 
links between stress, depression and the immune system. 
Accordingly, anti-inflammatory therapy, e.g. with the 
COX-2 inhibitor celecoxib, is effective in depression.
 The roles of microglial cells and astrocytes as media-
tors of inflammation in the brain are discussed, as is the 
influence of a disturbed blood-brain barrier (BBB) in fa-
cilitating the invasion of inflammatory molecules and im-
mune cells, including monocytes, T and B cells.
 The Cellular Basis of Inflammation in the Central 
Nervous System
 Microglia cells and astrocytes have been shown to play 
a central role in regulating neuroinflammation  [13, 14] . 
Astrocytes comprise approximately 80% of brain cells and 
are the most abundant type of glial cells in the central ner-
vous system (CNS), while microglial cells represent about 
15% of brain cells. Astrocytes have a strategic location: 
they are in close contact with CNS resident cells (neurons, 
microglia, oligodendrocytes and other astrocytes) and are 
part of the immune and inflammatory systems in the CNS. 
Among the cytokines, TNF-α, interferon (IFN)-γ, IL-1 
and IL-6 are the main astrocytic activators  [14] . Astro-
cytes are strongly involved in increased BBB permeability, 
endothelial cell activation, monocyte and microglia acti-
vation, and B cell survival and differentiation. Astrocytes 
produce and release a series of chemokines and are thus 
involved in the recruitment of monocytes and macro-
phages, dendritic cells and T and B cells in the CNS.
 Astrocytes, however, also store and release neurotrans-
mitters  [15] . For example, an important function of astro-
cytes is the regulation and storage of glutamate, which is 
actively transported into astrocytes  [16] . Therefore, as-
trocytes play a role not only as immune regulators and 
hosts of kynurenine metabolism, but also in the bioavail-
ability of neurotransmitters including glutamate, the 
most abundant neurotransmitter, which is involved in 
psychiatric disorders such as MD.
 BBB Disturbance in MD
 By far the most studies of biological parameters, in-
cluding immune parameters in MD, have examined com-
ponents of blood cells and serum, although the CSF re-
flects disturbances in the CNS much better. During acute 
inflammation, immune cells invade the CNS parenchyma 
through the disturbed BBB, i.e. through the endothelium 
of the small vessels and the tight junctions of astrocytes 
around the vessels. This invasion is mediated by cyto-
kines, chemokines, adhesion molecules and other media-
tors of inflammation. Signs of inflammation in the CNS 
are a disturbance of the BBB, increased immunoglobulins 
and, especially in acute inflammatory states, an increase 
in the cell number in the CSF.
 Analysis of the CSF is the gold standard for diagnosing 
CNS inflammatory disorders  [17, 18] . The rough method 
of ‘routine’ analysis of CSF parameters, however, only 
discovers gross changes in the CSF. More subtle changes 
in the CSF of MD patients may occur in a higher percent-
age of patients. Pathological changes in the CSF were ob-
served in a subgroup of around 25–30% of patients suf-
fering from MD  [19–21] . These changes included an in-
creased production of IgG and an increased BBB 
permeability, as is found in inflammatory states. Recent 
studies with the advanced CSF methodology have con-
firmed and extended these previous studies in that about 
15% of cases with therapy-resistant depression provide 
evidence of low-grade classical neuroinflammation, 
about 25% provide evidence of blood-CSF barrier dys-
function  [22] and, with some overlap to these pathologi-
cal findings, about 30% of patients demonstrate inflam-
matory activation patterns on CSF cells  [23] . In addition, 
more than 30% showed, with little overlap to the other 
findings, considerably increased CSF-neopterin, likely 
indicating some immune-inflammatory condition  [24] .
 The Model of ‘Sickness Behavior’ for Depression
 An animal model for MD is ‘sickness behavior’, i.e. the 
behavioral, vegetative, cognitive and emotional reaction 
of an organism to infection and inflammation  [25, 26] . In 
humans, the involvement of cytokines in the regulation 
of sickness behavior has been studied by administering 
the bacterial endotoxin lipopolysaccharide, LPS, to 
healthy volunteers  [27] . The levels of anxiety, depression 
and cognitive impairment were found to be related to the 
levels of circulating cytokines  [27, 28] .
 The Proinflammatory Immune State in MD
 A high blood level of CRP is a common marker for an 
inflammatory process. Higher than normal CRP levels 
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in severely depressed inpatients  [29] , and high CRP levels 
have been found to be associated with the severity of de-
pression  [30] . Higher CRP levels were also observed in 
remitted patients after a depressive state, in both men  [31, 
32] and women  [33, 34] . In a sample of older healthy per-
sons, CRP levels (and IL-6 levels) were predictive of cog-
nitive symptoms of depression 12 years later  [35] .
 Characteristics of immune activation in MD include in-
creased numbers of circulating lymphocytes and phago-
cytic cells, upregulated serum levels of markers of immune 
activation (neopterin, soluble IL-2 receptors), higher se-
rum concentrations of positive acute-phase proteins, 
APPs, coupled with reduced levels of negative APPs, and 
increased release of proinflammatory cytokines, such as 
IL-1β, IL-2, TNF-α and IL-6 through activated macro-
phages, and IFN-α through activated T cells  [3, 36–41] ( ta-
ble 1 ). Increased numbers of peripheral mononuclear cells 
in MD have been described by different research groups 
 [42–44] . In accordance with the findings of increased 
monocytes and macrophages, an increased level of neop-
terin has also been described  [45–48] . The role of cellular 
immunity, cytokines, the innate and the adaptive immune 
system in depression has been recently reviewed  [49, 50] .
 Infections and Autoimmune Disorders as Risk 
Factors for MD
 Results of a very interesting population-based Danish 
register study support the view that an infection or an auto-
immune disease significantly increases the risk of later de-
veloping a depressive disorder. This population-based pro-
spective cohort study of 78 million person-years includes 
3.6 million registered people (born between 1945 and 1996). 
The follow-up was documented from 1977 to 2010. All in-
dividuals with the diagnosis of an affective disorder accord-
ing to ICD-8, ICD-9 or ICD-10 were included in case they 
had had at least one hospital contact as an in- or outpatient 
due to affective disorder (including bipolar disorder). Every 
hospital contact due to an autoimmune disorder or infec-
tion (excluding HIV/AIDS) prior to psychiatric diagnosis 
was recorded and >91,000 affective disorder cases were 
identified, of which  ∼ 30,000 were diagnosed with infection 
and >4,000 were diagnosed with autoimmune disease.
 Hospitalization for infection significantly increased 
the risk of later mood disorder by 62% (incident rate ratio, 
IRR, 1.62), while hospitalization for autoimmune disease 
significantly increased the risk of later mood disorder by 
45% (IRR 1.45). The interaction of both risk factors in-
creased the risk to IRR 2.35. The risks were higher for 
hepatitis infection (IRR 2.82) compared to sepsis or CNS 
infections. The risk of mood disorder increased with the 
proximity to the infection, with the highest risk within the 
first year (IRR 2.70)  [51] .
 Inflammation Influences the Metabolism of 
Serotonin and Noradrenalin in Depression
 Overwhelming evidence collected over the last 40 years 
suggests that disturbances in serotonergic and noradren-
ergic neurotransmission are crucial factors in the patho-
genesis of MD  [52, 53] . Although the pathogenesis of the 
disturbed serotonergic and noradrenergic mechanisms is 
still unclear, the involvement of the proinflammatory im-
mune state might be crucial. The proinflammatory cyto-
kine IL-1β increases the metabolism of serotonin and nor-
adrenalin within the hypothalamus, prefrontal cortex, 
hippocampus and amygdala  [54–59] . Similar but less pro-
nounced effects on central monoamine activity after stim-
ulation with LPS or poly:IC have been observed for sev-
eral mediators such as IL-6 and TNF-α  [59, 60] .
 Similarly, administration of the proinflammatory cy-
tokine IFN-α is associated with reduced levels of sero-
tonin in the prefrontal cortex  [61] . Accordingly, symp-
toms of depression have been observed in many patients 
treated with IFN-α  [62, 63] .
 Moreover, two indirect pathways of the tryptophan/kyn-
urenine metabolism contribute to the induction of symp-
toms of depression by proinflammatory cytokines: (1) the 
increased metabolism of serotonin and (2) the increased 
production of N-methyl- D -aspartate (NMDA) agonists, i.e. 
glutamatergic products of kynurenine metabolism, after ac-
tivation of the enzyme indoleamine 2,3-dioxygenase (IDO) 
by proinflammatory cytokines  [64, 65] . Proinflammatory 
molecules such as PGE2 or TNF-α, however, induce the in-
crease of IDO activity synergistically with IFN  [66–68] .
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 Increased activity of the glutamatergic system in the 
peripheral blood of depressive patients has been repeat-
edly shown  [69–71] , although this result could not be rep-
licated by all groups  [72] . The inconsistency of the find-
ings, however, might be due to methodological problems 
 [73] . Support for increased glutamatergic activity in de-
pression comes from magnetic resonance spectroscopy: 
elevated glutamate levels were found in the occipital cor-
tex of unmedicated subjects with MD  [74] . Furthermore, 
NMDA antagonists such as MK-801  [75, 76] , ketamine 
 [77] , memantine  [78] , amantadine  [79, 80] and others 
 [73] have exhibited antidepressant effects in humans. The 
partial NMDA receptor agonist  D -cycloserine demon-
strated antidepressant effects at high doses  [81] .
 Several mechanisms can cause depressive states: (1) a 
direct influence of proinflammatory cytokines on sero-
tonin and noradrenalin metabolism  [60, 82, 83] ; (2) an 
imbalance of the type 1 and type 2 immune responses 
leading to increased tryptophan and serotonin metabo-
lism by activation of IDO in the CNS  [84, 85] ; (3) a de-
creased availability of tryptophan and serotonin  [47] , and 
(4) a disturbance of kynurenine metabolism, with an im-
balance in favor of the production of the NMDA receptor 
agonist quinolinic acid  [85, 86] .
 CNS Volume Loss in Neuroimaging Studies – 
A Consequence of an Inflammatory Process?
 A loss of brain volume has been observed in MD. Male 
patients with a first episode of MD had significantly 
smaller hippocampal total and grey matter volumes than 
healthy male comparison subjects  [87] . In a long-term 
study a significantly higher decline of volume in several 
CNS regions compared to healthy controls was observed 
 [88] . The pathophysiology of this volume loss is unclear. 
Glial reductions have been consistently found in brain 
circuits known to be involved in mood disorders, such as 
the limbic and prefrontal cortex  [89–93] . Recent studies 
have shown that the number of astrocytes is reduced in 
patients suffering from MD  [94–96] , although the data 
are not fully consistent  [97] .
 COX-2 Inhibition as an Example for an 
Anti-Inflammatory Therapeutic Approach in MD
 COX-2 inhibitors influence the CNS serotonergic sys-
tem, either directly or via CNS immune mechanisms. In 
a rat model, treatment with rofecoxib was followed by an 
increase of serotonin in the frontal and the temporopari-
etal cortex  [98] . Therefore, COX-2 inhibitors would be 
expected to show a clinical antidepressant effect. In the 
depression animal model of the bulbectomized rat, a de-
crease in hypothalamic cytokine levels and a change in 
behavior have been observed after chronic celecoxib 
treatment  [99] . In another animal model of depression, 
however, the mixed COX-1/COX-2 inhibitor acetylsali-
cylic acid showed an additional antidepressant effect by 
accelerating the antidepressant effect of fluoxetine  [100] . 
A significant therapeutic effect of the COX-2 inhibitor 
celecoxib in MD was also found in a randomized, double-
blind pilot add-on study of reboxetine and celecoxib ver-
sus reboxetine versus placebo  [101] . Interestingly, the ra-
tio of kynurenine to tryptophan, which represents the ac-
tivity of the proinflammatory cytokine-driven enzyme 
IDO, predicted the antidepressant response to the cele-
coxib therapy. Patients with a high activity of IDO, i.e. a 
high proinflammatory activity, responded better to cele-
coxib [Müller et al., submitted]. Another randomized, 
double-blind study in 50 depressed patients suffering 
from MD also showed a significantly better outcome with 
the COX-2 inhibitor celecoxib plus fluoxetine than with 
fluoxetine alone  [102, 103] . This finding was recently rep-
licated using the combination of sertraline and celecoxib 
in 40 depressed patients  [103] . Interestingly, the blood 
levels of IL-6 predicted the antidepressant response both 
in the sertraline (plus placebo) group and in the celecox-
ib (plus sertraline) group.
 The anti-TNF-α antibody infliximab, which blocks the 
interaction of TNF-α with cell-surface receptors and was 
developed for the therapy of inflammatory joint disorders 
and psoriasis, showed a highly significant effect on symp-
toms of depression in psoriasis patients  [104] . In a place-
bo-controlled add-on study using infliximab, however, 
an overall antidepressant effect could not be shown in a 
study of treatment-resistant depressed patients. Three in-
fusions of infliximab or placebo were given in a 12-week 
trial (n = 60) in partly medication-free (n = 23) nonre-
sponders to antidepressant therapy. No overall better 
outcome of infliximab versus placebo could be shown. 
There was, however, a significant interaction between 
treatment, time and baseline CRP ( ≤ 5 mg/l): patients 
with higher baseline CRP had a higher response rate to 
infliximab (62%) versus placebo (33%). Moreover, the 
baseline concentrations of TNF-α, sTNFR1 and sTNFR2 
were significantly higher in infliximab responders (p  ≤ 
0.01). Additionally, infliximab responders exhibited a 
significantly higher decrease of CRP (p  ≤ 0.01) than non-
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findings that the angiotensin II AT1 receptor blockade 
has anti-inflammatory effects in the CNS and ameliorates 
stress, anxiety and CNS inflammation  [106, 107] .
 Inflammatory Pathogenesis in MD and 
Schizophrenia – The End of the Kraepelinian 
Dichotomy?
 The Kraepelinian dichotomy of schizophrenia and af-
fective disorder has been discussed for many years. Sev-
eral findings of modern biological psychiatry show an 
overlap of both disorders and genetic researchers postu-
late, in particular, that new diagnostic classifications 
which have greater biological validity will in the future 
allow the selection of treatments based on the underlying 
pathogenesis  [108] . With respect to the mechanisms of 
inflammation, different patterns of type 1 and type 2 im-
mune activation seem to be associated with schizophre-
nia versus MD [109] . The large table of immune and in-
flammatory genes involved makes it plausible that vari-
ous types of immune balance may be involved. 
Differences in immune activation may have different im-
pacts on the IDO activation and the tryptophan/kynuren-
ine metabolism, which then may result in increased pro-
duction of kynurenic acid in schizophrenia and increased 
quinolinic acid levels in depression. Such differences may 
be associated with an imbalance in the glutamatergic neu-
rotransmission, contributing to an exaggerated NMDA 
activity in depression and NMDA antagonism in schizo-
phrenia. Moreover, differential activation of microglia 
cells and astrocytes in schizophrenia and depression may 
be an additional mechanism to increased production of 
PGE2 and increased expression of COX-2.
 Although there is strong evidence for the view that the 
interactions of the immune system, IDO, serotonergic 
system and glutamatergic neurotransmission play a key 
role in schizophrenia and depression, several gaps, for ex-
ample the roles of genetics, disease course, sex, different 
psychopathological states, etc., have to be bridged by fur-
ther intense research. Moreover, COX-2 inhibition is 
only one example of possible therapeutic mechanisms 
acting on these mechanisms. Also, the effects of COX-2 
inhibition in the CNS as well as the different components 
of the inflammatory system, the kynurenine metabolism 
and the glutamatergic neurotransmission need further 
careful scientific evaluation.
 Moreover, similar pathological influences may lead 
to different psychopathological states due to different 
localizations of the pathological processes in the CNS. 
Neuropathological and neuroimaging studies show
that – albeit with a broad range of overlap – different 
brain regions are involved in schizophrenia (e.g. the hip-
pocampus  [110, 111] ) and depression (e.g. the habenula 
 [112, 113] ).
 Despite some common pathways, different final path-
ways may lead to different syndromes of schizophrenia 
and depression. Inflammation, including low-grade in-
flammation, is a general pathway of the body represent-
ing a response to a lot of different noxae and pathogens. 
Despite some overlap, which is apparent between patho-
physiological mechanisms identified in schizophrenia 
and affective disorders, the differential mechanisms are 
also of major interest. Similar phenomena, overlap and 
some specificity are found in medicine in general, and not 
only in psychiatry. To develop preventive strategies in 
high-risk individuals and patients  [114] , such refined un-
derstanding is of immense interest.
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